[Controlled clinical trial of a new synthetic preparation (parsalmide) in the treatment of inflammatory and degenerative arthro-myopathies].
A double-blind, between-patients trial of a new drug (parsalmide) against indomethacin in the relief of inflammation and pain in 68 patients with exacerbated inflammatory and-or degenerative arthromyopathy resulted in 76% of successful results with both drugs. Tolerance was good, though side-effects, albeit slight, were more common with indomethacin.
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D007592:Joint Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000188:drug therapy; D012585:Sciatica / Q000188:drug therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001549:Benzamides; D007213:Indomethacin
Sperimentazione clinica controllata di un nuovo preparato di sintesi (parsalmide) nel trattamento delle artro-miopatie infiammatorie e degenerative